Clinical implications of repeated drug monitoring of imatinib in patients with metastatic gastrointestinal stromal tumour

BACKGROUND: Imatinib mesylate (IM) is the preferred treatment for the majority of patients with metastatic gastrointestinal stromal tumour (GIST). Low trough IM concentration (C(min)) values have been associated with poor clinical outcomes in GIST patients. However, there are few studies of repeated...

Descripción completa

Detalles Bibliográficos
Autores principales: Hompland, Ivar, Bruland, Øyvind Sverre, Ubhayasekhera, Kumari, Bergquist, Jonas, Boye, Kjetil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5157085/
https://www.ncbi.nlm.nih.gov/pubmed/27999655
http://dx.doi.org/10.1186/s13569-016-0062-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5157085/
https://www.ncbi.nlm.nih.gov/pubmed/27999655
http://dx.doi.org/10.1186/s13569-016-0062-2

Ejemplares similares